BioNexus Gene Lab (BGLC) Receivables (2019 - 2026)

BioNexus Gene Lab's Receivables history runs 8 years deep, the most recent figure standing at $168843.0 for Q1 2026.

• In Q1 2026, Receivables fell 89.94% year-over-year to $168843.0; the TTM figure through Mar 2026 stood at $168843.0 (down 89.94% YoY), while the FY2025 annual figure was $587613.0, down 62.81% from the prior year.
• Receivables came in at $168843.0 for Q1 2026 at BioNexus Gene Lab, down from $587613.0 in the prior quarter.
• In the past five years, Receivables ranged from a high of $3.1 million in Q1 2022 to a low of $168843.0 in Q1 2026.
• A 5-year average of $1.8 million and a median of $1.6 million in 2025 frame the typical range for Receivables.
• Across the five-year window, Receivables jumped 77.39% in 2025 and plunged 89.94% in 2026, its largest moves.
• BioNexus Gene Lab's Receivables stood at $2.9 million in 2022, then slumped by 68.13% to $922106.0 in 2023, then jumped by 71.37% to $1.6 million in 2024, then sank by 62.81% to $587613.0 in 2025, then slumped by 71.27% to $168843.0 in 2026.
• According to Business Quant data, Receivables over the past three periods registered $168843.0, $587613.0, and $1.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison